Floatz Rating
B62/100
Confidence
Indicative
Sponsor
Biotheus Inc.
Modality
monoclonal_antibody
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
52Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06616532CT.gov PM8002 in Combination With Paclitaxel Compared With Chemotherapy as Second-line Treatment in Small Cell Lung Cancer | — | Active Not Recruiting | — | — | — |
NCT05844150CT.gov A Study of PM8002 (Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With ES-SCLC | — | Active Not Recruiting | — | — | — |
NCT05879068CT.gov A Study of PM8002 in Combination With Chemotherapy in Patients With SCLC | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Small Cell Lung Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| pm8002 (this asset) | Biotheus Inc. | P3 | B · 62 |
| Benmelstobart | Yayi He | P4 | A |
| Anti-Pd-L1 Monoclonal Antibody Shr-1316 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | P3 | BBB |
| Berzosertib | National Cancer Institute (NCI) | P2 | BBB |
| Etoposide | Sichuan University | P4 | BBB |
| Cis-Diamminedichloroplatinum Ii | National Cancer Institute (NCI) | P4 | BBB |
| Veliparib | Central European Society for Anticancer Drug Research | P2 | BB |
| Carboplatin | University of Maryland, Baltimore | P4 | BB |
| hs-20093 | Shanghai Hansoh Biomedical Co., Ltd | P3 | BB |
+42 more in the Small Cell Lung Carcinoma cohort
Other indications for pm8002
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Triple-Negative Breast Carcinoma | — | P3 | B · 62 |
| Hepatocellular Carcinoma | — | P2 | CCC · 54 |
| Non-Small Cell Lung Carcinoma | — | P2 | CCC · 53 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. pm8002 in Small Cell Lung Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/pm8002-small-cell-lung-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →